Phenomenex Launches PhenoAcademy for Cutting-Edge Chromatography Education tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Tangential Flow Filtration Market to Reach a Valuation of US$ 4.2 Billion at 13% CAGR by 2033, States Fact.MR forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
By Qu Song "We have tangibly felt the constant optimization of China's business environment in the recent years," said Edward Zhou, president of Cytiva China, a subsidiary of the global life sciences leader, recalling how the company settled in Lingang new area of the Shanghai free trade zone (FTZ). According…
Global Roundup: Switzerland's BioVersys Secures CARB-X Funds for Multidrug Resistant Research - read this article along with other careers information, tips and advice on BioSpace
/PRNewswire/ Precision NanoSystems (PNI) has been acquired by Danaher Corporation s Life Sciences platform. PNI is a global leader in technologies and.
45 Meanwhile, this protective effect of CypA was also found in cardiomyocytes. 46 Oxidative stress is believed to contribute to asthma pathogenesis, and a previous study reported that antioxidant therapy can be useful for asthma. 47 Therefore, the mechanisms of CypA on oxidative stress involved in asthma should be noted. Thus far, our understanding of the mechanisms of CypA is far from complete. The role of CypA in the functioning of asthma with regard to the mechanism of reducing the RL and the isometric tension of tracheal spiral is unknown and is the subject of further study. Conclusion In summary, this work has demonstrated the effects of rCypA in asthma in both OVA-challenged asthmatic rats in vivo and ACh-induced contraction tracheal spirals ex vivo. The study also identified the underlying mechanism by which rCypA may have a precise role in limiting inflammation in asthma by suppressing the secretion of Th2 cytokines and balancing the ratio of Th1/Th2 cytokines, indicating that CypA may serve as a potential novel therapeutic strategy for asthma.